HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.
Read original at benzingaStocks · News reference
Korro Bio Submits To Australian Alfred Health Human Ethics Committee To Start Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
https://www.sec.gov/ix?doc=/Archives/edgar/data/1703647/000119312526356877/krro-20260819.htm
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 19, 2026, 8:11 PM
- Checked
- Aug 19, 2026, 8:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Korro Bio, Inc. (KRRO)
Filed: 2026-08-19 AccNo: 0001193125-26-356877 Size: 174 KB Item 8.01: Other Events
Read original at edgarKorro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the
Read original at benzinga